ONO Pharmaceutical Co (OPHLF) Stock Statistics & Valuation Metrics

ONO Pharmaceutical Co has a market cap or net worth of $6.72B. The enterprise value is $960.85B.

Market Cap

$6.72B

Enterprise Value

$960.85B

ONO Pharmaceutical Co has 498,692,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

498,692,800

Owned by Insiders

―

Owned by Institutions

11.84%

ONO Pharmaceutical Co’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 7.95%.

Return on Equity (ROE)

0.08

Return on Assets (ROA)

0.06

Return on Invested Capital (ROIC)

7.95%

Return on Capital Employed (ROCE)

0.11

Revenue Per Employee

122.63M

Profits Per Employee

16.59M

Employee Count

4,206

Asset Turnover

0.47

Inventory Turnover

2.47

The current PE Ratio of ONO Pharmaceutical Co is 14.21. ONO Pharmaceutical Co’s PEG ratio is 0.26.

PE Ratio

14.21

PS Ratio

2.16

PB Ratio

1.21

Price to FCF

8.33

Price to Operating Cash Flow

8.00

PEG Ratio

0.26

In the last 12 months, ONO Pharmaceutical Co had revenue of 515.78B and earned 69.77B in profits. Earnings per share was 148.49.

Revenue

515.78B

Gross Profit

374.07B

Operating Income

103.33B

Pretax Income

92.65B

Net Income

69.77B

EBITDA

133.94B

Earnings Per Share (EPS)

148.49

In the last 12 months, operating cash flow was 132.56B and capital expenditures -5.37B, giving a free cash flow of 127.19B billion.

Operating Cash Flow

132.56B

Free Cash Flow

127.19B

Free Cash Flow per Share

270.59

ONO Pharmaceutical Co pays an annual dividend of $0.25, resulting in a dividend yield of 3.59%

Dividend Per Share

$0.25

Dividend Yield

3.59%

Payout Ratio

81.64%

Free Cash Flow Yield

12.00%

Earnings Yield

7.04%

Beta

0.57

52-Week Price Change

15.57%

50-Day Moving Average

15.04

200-Day Moving Average

14.66

Relative Strength Index (RSI)

39.49

Average Volume (3m)

2,051

ONO Pharmaceutical Co upcoming earnings date is Feb 01, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Feb 01, 2027

Ex-Dividend Date

Mar 31, 2026

ONO Pharmaceutical Co as a current ratio of 2.86, with Debt / Equity ratio of 14.22%

Current Ratio

2.86

Quick Ratio

2.51

Debt to Market Cap

0.09

Net Debt to EBITDA

-0.87

Interest Coverage Ratio

29.20

In the past 12 months, ONO Pharmaceutical Co has paid 22.74B in taxes.

Income Tax

22.74B

Effective Tax Rate

0.25

ONO Pharmaceutical Co EV to EBITDA ratio is 6.64, with an EV/FCF ratio of 7.17.

EV to Sales

1.86

EV to EBITDA

6.64

EV to Free Cash Flow

7.17

EV to Operating Cash Flow

6.88

ONO Pharmaceutical Co has $258.26B in cash and marketable securities with $109.99B in debt, giving a net cash position of $148.27B billion.

Cash & Marketable Securities

$258.26B

Total Debt

$109.99B

Net Cash

$148.27B

Net Cash Per Share

$297.32

Tangible Book Value Per Share

$1,099.08

Gross margin is 74.11%, with operating margin of 22.08%, and net profit margin of 15.19%.

Gross Margin

74.11%

Operating Margin

22.08%

Pretax Margin

20.14%

Net Profit Margin

15.19%

EBITDA Margin

27.96%

EBIT Margin

20.38%

The average price target for ONO Pharmaceutical Co is $13.98, which is 11.43% higher than the current price. The consensus rating is Moderate Sell

Price Target

$13.98

Price Target Upside

0.83% Downside

Analyst Consensus

Moderate Sell

Analyst Count

1

Revenue Growth Forecast

-7.54%

EPS Growth Forecast

43.99%